Greenspan Ira Scott 4
4 · Scopus BioPharma Inc. · Filed Feb 26, 2021
Insider Transaction Report
Form 4
Greenspan Ira Scott
Director
Transactions
- Purchase
Common Stock, par value $0.001
2021-02-24$9.48/sh+115$1,090→ 80,790 total - Purchase
Common Stock, par value $0.001
2021-02-24$9.45/sh+300$2,835→ 6,950 total(indirect: HCFP) - Purchase
Common Stock, par value $0.001
2021-02-25$9.01/sh+800$7,208→ 7,750 total(indirect: HCFP)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.69 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]Mr. Greenspan is deemed to have shared voting and dispositive power over HCFP-held securities. Mr. Greenspan disclaims beneficial ownership of shares by this entity, except to the extent of his proportionate pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.00 to $9.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.